Direct answer: Semaglutide continues to regulate appetite, slow digestion, and improve blood sugar control over time
Multiple endocrine neoplasia syndrome type 2 (MEN2)
A new clinical trial, co-led by endocrinologist and diabetes expert John Buse, MD, PhD, and interventional cardiologist Matthew Cavender, MD, MPH, at the UNC School of Medicine has shown that the oral form of semaglutide can significantly reduce cardiovascular events in people with type 2 diabetes and atherosclerotic cardiovascular disease, and/or chronic kidney disease
Motus (oral) reported notable human clinical trial results for an oral supplement, and that difference - oral versus injectable - matters for many peoples preferences and lifestyles
Following treatment with Semaglutide Cleveland patients generally tolerate the medication well, though some may experience mild side effects such as nausea, vomiting, diarrhea, or constipation